We Are Crinetics

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Watch Our Video

Read the Latest

November 23, 2020

Crinetics Pharmaceuticals to Participate in December Investor Conferences

Dr. Scott Struthers and Dr. Alan Krasner present at 32nd annual Piper Sandler Healthcare Conference December 1st-3rd, 2020 Webcast available until December 3rd.

November 16, 2020

Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology

“Dr. Trainer is a global leader in the endocrine community who has treated patients, published extensively and educated physicians on the identification and treatment of endocrine disease, particularly in the area of neuroendocrinology,” said Alan S. Krasner, M.D., Chief Medical Officer of Crinetics.

Pipeline

We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and endocrine oncology such as:

Our investigational drug for acromegaly is entering Phase 3. But that’s just at the forefront of the important work we’re doing to combat endocrine disease.
See the science >

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (oral SST2 agonist)
Acromegaly
Paltusotine (oral SST2 agonist)
Neuroendocrine Tumors (NETs)
CRN04777 (oral SST5 agonist)
Congenital Hyperinsulinism (congenital HI)
Oral ACTH Antagonist
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
Undisclosed Novel Program

Press Releases

Investor Relations

Investor Relations Crinetics Pharmaceuticals

News